(Reuters) – The U.S. Food and Drug Administration on Friday approved ChemoCentryx Inc’s lead drug candidate, Avacopan, for treating a rare, fatal autoimmune disease, the biopharmaceutical company said.
(Reporting by Oishee Majumdar and Dania Nadeem in Bengaluru; Editing by Anil D’Silva)
